CYRX - Cryoport, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
15.04
+0.35 (+2.38%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.69
Open14.73
Bid14.00 x 800
Ask16.00 x 800
Day's Range14.58 - 15.16
52 Week Range8.28 - 25.02
Volume240,845
Avg. Volume562,503
Market Cap539M
Beta (5Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Cryoport Revenue Grows 81% for Third Quarter 2019
    PR Newswire

    Cryoport Revenue Grows 81% for Third Quarter 2019

    Cryoport now supports 425 clinical trials in Regenerative Medicine market Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially IRVINE, Calif. , Nov. 7, 2019 ...

  • Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
    PR Newswire

    Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy

    - Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis - Partnership incorporates Cryoport's Cryoportal® Logistics Management Platform, SmartPak ...

  • Cryoport to Report Third Quarter 2019 Financial Results on November 7, 2019
    PR Newswire

    Cryoport to Report Third Quarter 2019 Financial Results on November 7, 2019

    IRVINE, Calif., Oct. 31, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2019 on Thursday, November 7, 2019 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, November 7, 2019. Cryoport management will host a conference call at 5:00 pm ET on November 7, 2019.

  • Cryoport Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences
    PR Newswire

    Cryoport Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences

    IRVINE, Calif. , Oct. 9, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the ...

  • GlobeNewswire

    Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

    PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, announce a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies. This agreement with Cryoport will contribute to this, alongside other solutions including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals. “Control and monitoring are critical because a simple temperature variation can jeopardize these cells and, ultimately, the product we supply to patients.

  • Cryoport Introduces Cell & Gene Industry's First Dedicated Shipper for Advanced Therapies
    PR Newswire

    Cryoport Introduces Cell & Gene Industry's First Dedicated Shipper for Advanced Therapies

    IRVINE, Calif., Sept. 18, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced the launch of its Advanced Therapy Shipper™ product line for the regenerative medicine market. The Advanced Therapy Shipper™ guarantees each shipper has been used only for human use and provide complete traceability of all equipment, components and commodities.  The result is unmatched verification information and unmatched supply chain support for biopharma companies researching and commercializing cell and gene therapies.

  • GlobeNewswire

    Vineti and Cryoport Collaborate to Bring Integrated Solutions to the Global Regenerative Therapy Market

    Collaboration between industry-leading supply chain orchestration (SCO) platform and the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities will bring the capabilities to support hundreds of advanced therapy clinical centers, clinical trials and commercially approved products worldwide. SAN FRANCISCO and IRVINE, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Vineti, Inc., and  Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) announced a commercial partnership designed to extend end-to-end delivery of cell therapies and gene therapies to a growing number of patients as the industry continues to scale. Pairing Vineti’s supply chain orchestration (SCO) platform with Cryoport’s integrated temperature-controlled capabilities and near real-time monitoring will provide an end-to-end solution for advanced therapies, supporting the assurance of improved drug product quality and patient safety.  Vineti and Cryoport together seek to leverage both of their commercial and clinical phase experiences and insights from serving biopharma customers.

  • GlobeNewswire

    BriaCell Appoints Richard J. Berman to Board of Directors

    BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • Cryoport Revenue Grows 83% for Second Quarter 2019
    PR Newswire

    Cryoport Revenue Grows 83% for Second Quarter 2019

    Cryoport now supports 413 clinical trials in regenerative medicine Cryoport supports the commercial launch of bluebird bio's Zynteglo™ in Europe IRVINE, Calif. , Aug. 8, 2019 /PRNewswire/ -- Cryoport, ...

  • Cryoport to Report Second Quarter 2019 Financial Results on August 8th, 2019
    PR Newswire

    Cryoport to Report Second Quarter 2019 Financial Results on August 8th, 2019

    In addition to the earnings release, a document titled "Cryoport Second Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, August 8. Cryoport management will host a conference call at 5:00 pm ET on August 8, 2019.

  • Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain
    PR Newswire

    Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain

    IRVINE, Calif., July 11, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.

  • Cryoport Announces Pricing of Public Offering of Common Stock
    PR Newswire

    Cryoport Announces Pricing of Public Offering of Common Stock

    IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) ("Cryoport" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 3,750,000 newly issued shares of common stock at a price of $17.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock. The net proceeds to the Company from the offering of the shares are expected to be approximately $59.8 million after deducting underwriting discounts and commissions and estimated offering expenses, and assuming no exercise of the underwriters' option to purchase additional shares.

  • Cryoport Announces Proposed Public Offering of Common Stock
    PR Newswire

    Cryoport Announces Proposed Public Offering of Common Stock

    IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) ("Cryoport" or the "Company") today announced that it intends to offer shares of common stock in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). Cryoport also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering are to be sold by Cryoport.

  • Cryoport to Ring the Nasdaq Closing Bell on Monday, June 10 and Attend Jefferies 2019 Healthcare Conference June 4ᵗʰ-7ᵗʰ, 2019
    PR Newswire

    Cryoport to Ring the Nasdaq Closing Bell on Monday, June 10 and Attend Jefferies 2019 Healthcare Conference June 4ᵗʰ-7ᵗʰ, 2019

    IRVINE, Calif., June 5, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) (or the "Company"), the world's leading temperature-controlled supply chain company dedicated to the life sciences industry, today announced its Chief Executive Officer, Jerrell Shelton, and other members of the management team, will ring the Nasdaq closing bell on Monday, June 10, 2019. Jerrell Shelton will be interviewed live on the "The Watch List" on the TD Ameritrade Network, on Monday, June 10, 2019 at 1:00PM Eastern Time. The Cryoport closing bell ceremony will be broadcast live starting at 3:45pm Eastern Time from the Nasdaq MarketSite Tower in New York City.

  • PR Newswire

    CalAmp Announces Research Collaboration with Cryoport to Develop Next Generation Condition Monitoring System

    IRVINE, Calif., May 16, 2019 /PRNewswire/ -- CalAmp (CAMP), an advanced technology solutions pioneer transforming the global connected economy, today announced a strategic collaboration with Cryoport (CYRX) (Nasdaq:CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, to develop a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. This research and development collaboration is aimed at enhancing the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.

  • Cryoport Expands into Biostorage through the Acquisition of Cryogene
    PR Newswire

    Cryoport Expands into Biostorage through the Acquisition of Cryogene

    IRVINE, Calif., May 14, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that it has expanded its suite of temperature-controlled solutions to include biostorage for the life sciences through its acquisition of Cryogene Partners ("Cryogene"), a Houston-based company. Cryogene operates a recently expanded 21,000 square foot state-of-the-art biostorage facility, specializing in the secure storage of biological specimens, materials and samples.

  • Cryoport to Host Workshop at 14th Annual World Advanced Therapies & Regenerative Medicine Congress on Wednesday, May 15th
    PR Newswire

    Cryoport to Host Workshop at 14th Annual World Advanced Therapies & Regenerative Medicine Congress on Wednesday, May 15th

    IRVINE, Calif., May 9, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, announced today its 2nd annual workshop, titled, 'Process Considerations for Cryogenic and Regenerative Medicine Commercialization,' taking place on Wednesday, May 15, 2019 at the Business Design Centre in London, United Kingdom. The educational workshop is taking place in conjunction with the World Advanced Therapies & Regenerative Medicine Congress event and is aimed at biotechnology and pharmaceutical professionals who want to learn more about the critical considerations for the development and commercialization of vital regenerative medicine therapies.

  • Cryoport Revenue Grows 65% for First Quarter 2019
    PR Newswire

    Cryoport Revenue Grows 65% for First Quarter 2019

    Commercial revenue rises to 25% of total biopharma revenue; 383 clinical trials supported IRVINE, Calif. , May 2, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" ...

  • Cryoport to Report First Quarter 2019 Financial Results on May 2nd, 2019
    PR Newswire

    Cryoport to Report First Quarter 2019 Financial Results on May 2nd, 2019

    In addition to the earnings release, a document titled "Cryoport First Quarter 2019 in Review," which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, May 2. Cryoport management will host a conference call at 5:00 pm ET on May 2, 2019. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results.

  • Celularity Selects Cryoport's Temperature Controlled Logistics Solutions
    PR Newswire

    Celularity Selects Cryoport's Temperature Controlled Logistics Solutions

    IRVINE, Calif. , April 11, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences ...

  • GlobeNewswire

    Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Biokin Pharmaceutical Selects Cryoport's Temperature-Controlled Solutions for its Pending Phase I and Phase II trials
    PR Newswire

    Biokin Pharmaceutical Selects Cryoport's Temperature-Controlled Solutions for its Pending Phase I and Phase II trials

    CHENGDU, China and SEATTLE and IRVINE, California , March 28, 2019 /PRNewswire/ -- Biokin Pharmaceutical Co. Ltd., ("Biokin Pharma") a leading pharmaceutical company with operations in China ...

  • Cryoport Reports 64% Growth for Fiscal Year 2018
    PR Newswire

    Cryoport Reports 64% Growth for Fiscal Year 2018

    Cryoport now supports 357 clinical trials in the Americas and EMEA with 47 in Phase III IRVINE, Calif. , March 7, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" ...

  • Cryoport to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 7th, 2019
    PR Newswire

    Cryoport to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 7th, 2019

    In addition to the earnings release, a document titled "Cryoport 2018 Year in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business outlook, will be issued by management at 4:05 pm EST on Thursday, March 7. Cryoport management will host a conference call at 5:00 pm EST on March 7, 2019.